The CancerConnect Neuroendocrine Tumors Newsletter

TraceyS

Stay Current With Neuroendocrine Tumors Treatment Advances & Connect with Others

CancerConnect publishes daily cancer news, original articles and "tips" on the management of Neuroendocrine Tumors. These are available in our monthly Neuroendocrine Tumors newsletter.

Stay Current - Connect With Other Neuroendocrine Tumors Patients

Join The CancerConnect Community: Connect with others and receive regular updates

Sign up for the Neuroendocrine Tumors Newsletter Here

Comments

Neuroendocrine Tumors

FEATURED

COMMUNITY

Lutathera Pepetide Receptor Radionuclide Therapy for NETs

Cancer Connect

Afinitor Promising in Neuroendocrine Tumors Originating in GastrointestinalTract

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

Cancer Connect

CancerConnect Launches On line Community for Patients with Neuroendocrine Tumors

Cancer Connect

FDA Approves Lutathera for Treatment for Certain Digestive Tract Cancers

Cancer Connect

Azedra® - Frequently Asked Questions About Azedra® (iobenguane I 131)

Understand the administration, side effects and answers to frequently asked questions about Azedra® (iobenguane I 131)

TraceyS

FDA Designates Therapy for Azedra in Pheochromocytoma and Paraganglioma

FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

Cancer Connect

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors

Cancer Connect

Xermelo-new option for controlling symptoms of Carcinoid Syndrome

Cancer Connect

Sutent Delays Progression of Pancreatic Neuroendocrine Tumors

Cancer Connect

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET)

Cancer Connect